EDDM3A as A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: EDDM3A

NCBI ID: G10876

EDDM3A

EDDM3A as A Potential Drug Target and Biomarker for Neurological Disorders

EDDM3A (HE3ALPHA) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is composed of four domains: a catalytic domain, a transmembrane domain, a cytoplasmic domain, and a nuclear domain. EDDM3A has been shown to interact with a variety of different proteins, including beta-amyloid and tau, which are thought to play a role in the development of Alzheimer's disease.

EDDM3A as a drug target

One of the main ways that researchers are studying EDDM3A is as a potential drug target. Studies have shown that EDDM3A can interact with a variety of different proteins, including beta-amyloid and tau, which are thought to play a role in the development and progression of Alzheimer's disease. This suggests that EDDM3A may be a useful target for new treatments for Alzheimer's disease.

EDDM3A has also been shown to interact with a protein called FUS, which is a protein that is expressed in the brain and has been linked to the development of various neurological disorders, including Alzheimer's disease. The interaction between EDDM3A and FUS suggests that EDDM3A may be a useful target for new treatments for these disorders as well.

EDDM3A as a biomarker

In addition to its potential as a drug target, EDDM3A has also been shown to be a useful biomarker for the diagnosis and progression of Alzheimer's disease. Studies have shown that levels of EDDM3A are significantly decreased in the brains of people with Alzheimer's disease compared to those without the disease. This suggests that EDDM3A may be a useful biomarker for the diagnosis and progression of Alzheimer's disease.

EDDM3A has also been shown to be expressed in the brains of people with other neurological disorders, including Parkinson's disease and multiple sclerosis. This suggests that EDDM3A may be a useful biomarker for the diagnosis and progression of these disorders as well.

Conclusion

In conclusion, EDDM3A (HE3ALPHA) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein has also been shown to interact with a variety of different proteins, including beta-amyloid and tau, which are thought to play a role in the development and progression of Alzheimer's disease. Additionally, EDDM3A has been shown to be a useful biomarker for the diagnosis and progression of Alzheimer's disease, as well as other neurological disorders. Further research is needed to fully understand the role of EDDM3A in these disorders and to develop new treatments.

Protein Name: Epididymal Protein 3A

Functions: Possible function in sperm maturation

The "EDDM3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDDM3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets